Mittie Doyle, Chief Medical Officer at Avalo Therapeutics, Inc. (AVTX), sold 3,970 shares at $18.01 ($72K) on 2026-04-06, disclosed to the SEC on 2026-04-08.
Scheduled sale ($72k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AVTX | SELL | 2026-08-12 | $14K | — | Filing → |
| AVTX | SELL | 2026-07-29 | $20K | — | Filing → |
| AVTX | SELL | 2026-07-02 | $93K | — | Filing → |